Insider Trading History of Foresite Capital Opportunity Management V, Llc

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of Foresite Capital Opportunity Management V, Llc since 2021. This trader's CIK number is 1792207. At the time of last reporting, Foresite Capital Opportunity Management V, Llc was the 10% Owner of Kinnate Biopharma Inc.. (stock ticker symbol KNTE). Also see all insider trading activities at Kinnate Biopharma Inc..

Note that in the past Foresite Capital Opportunity Management V, LLC also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Pardes Biosciences, Inc. (PRDS) by Foresite Capital Opportunity Management V, Llc

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2021 PRDS 325,000 $3,250,000 0 $0 0 $0

Yearly summary of insider trading at Kinnate Biopharma Inc. (KNTE) by Foresite Capital Opportunity Management V, Llc

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2023 KNTE 1,780,000 $4,984,000 0 $0 0 $0


Insider trading activities at 2 companies by Foresite Capital Opportunity Management V, Llc:

1. Pardes Biosciences, Inc. (PRDS)

2. Kinnate Biopharma Inc. (KNTE)

Table 1. Insider trading of Pardes Biosciences, Inc. (PRDS) by Foresite Capital Opportunity Management V, Llc

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2021-12-22 PRDS Buy 325,000 10.00 3,250,000

Table 2. Insider trading of Kinnate Biopharma Inc. (KNTE) by Foresite Capital Opportunity Management V, Llc

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2023-05-08 KNTE Buy 1,780,000 2.80 4,984,000

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Foresite Capital Opportunity Management V, Llc (10% Owner of Kinnate Biopharma Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.